ACER - FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

• Acer Therapeutics ( NASDAQ: ACER ) and partner Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders.
• The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date.
• Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading.
• The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application .
• The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.

For further details see: